Table 1.

Baseline Demographic and Clinical Characteristics

Characteristic		Number (N=1002)	%
Age (year)
	Median (range)	70 (46–93)
Tumor Stage
	≤T1c, T2a	719	72
	T2b–T2c	141	14
	≥T3a	120	12
	Unknown (Tx)	22	2
Gleason Score
	2 – 6	306	30.5
	7	490	48.9
	8 – 10	206	20.6
PSA
	≤10 ng/mL	668	66.7
	>10 ng/mL	334	33.3
Risk group
	Very Low risk	96	9.6
	Low risk*	100	10
	Low risk‡	196	19.6
	Intermediate risk	462	46.1
	High risk	344	34.3
ADT use
	Yes	589	58.8
	Duration ≤6 months	277	47
	Duration >6 months	312	53
Percent Core Involvement
	Median (range) (%)	37.5 (4–100)
IPSS
	Total Available	640	64
	Median (range)	8 (0 – 35)
	≤15	542	85
	>15	98	15
Baseline Sexual Function
	Full Potency	427	42.7
	Partial Potency	277	27.6
	Impotent	267	26.6
	Unknown	31	3.1

Note: Risk grouping based upon the National Comprehensive Cancer Network (NCCN) risk classification.

Abbreviations: ADT, androgen-deprivation therapy; IPSS, International Prostate Symptom Score; PSA, prostate-specific antigen

^*New NCCN low-risk group, excluding very-low-risk patients

^‡Classic NCCN low risk group that combines the new very low risk and low risk groups together